GlassScriptPhysician profile
Stephanie A Suber
NPI 1043419690
$9,939.34
in general payments reported to CMS, 2019-2025
68 companies · $1,637 in 2025
The $1,637 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,501 · 2020: $339 · 2021: $1,706 · 2022: $1,725 · 2023: $1,686 · 2024: $1,345 · 2025: $1,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,479 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,478.67 |
| Education | $188.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,517.60 | 2021-2025 | Ubrelvy, Vraylar, Synthroid |
| Novo Nordisk INC | $869.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $710.25 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $452.35 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $437.83 | 2019-2025 | Gardasil 9, Capvaxive, Belsomra |
| Amgen INC. | $407.40 | 2019-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $405.24 | 2023-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $394.04 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $325.51 | 2019-2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $312.51 | 2019-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.94 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $218.95 | 2019-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $217.37 | 2023-2025 | Auvelity, Symbravo |
| Corium, LLC | $200.48 | 2022-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $197.92 | 2022-2025 | Caplyta |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Suber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.